Peptides in Sports Medicine: The Evidence
Peptides in Sports Medicine
544 studies screened
A 2025 systematic review screened 544 BPC-157 articles for orthopaedic sports medicine applications. Only one clinical study met inclusion criteria.
Vasireddi et al., HSS Journal, 2025
Vasireddi et al., HSS Journal, 2025
View as imageThe peptide market in sports and athletic recovery has expanded dramatically, driven by social media, podcast culture, and a growing network of clinics offering injectable peptide therapies. The disconnect between this commercial growth and the underlying evidence is stark. Some peptides used in sports medicine contexts have randomized controlled trial data in humans; others have extensive preclinical data but no completed human trials; and a third category is prohibited by the World Anti-Doping Agency (WADA) regardless of evidence quality. This article separates these tiers, covering what the legitimate research actually shows for each peptide class used in sports medicine. For deeper coverage of specific peptides, see our articles on BPC-157 for sports injuries, TB-500 and athletic recovery, and collagen peptides for athletes.
Key Takeaways
- A systematic review of BPC-157 in orthopaedic sports medicine screened 544 articles but found only 1 clinical study meeting inclusion criteria, with 42 of 43 included studies being animal research (Vasireddi et al., HSS Journal, 2025)
- Daily 10g collagen peptide supplementation for 16 weeks significantly increased both muscle stiffness and tendon stiffness in healthy young males, with enhanced explosive strength, in a double-blind RCT of 50 participants (Miyamoto et al., Medicine and Science in Sports and Exercise, 2025)
- Specific bioactive collagen peptides increased patellar tendon cross-sectional area by 11.0% versus 4.7% for placebo during 15 weeks of resistance training in a double-blind RCT (Balshaw et al., Medicine and Science in Sports and Exercise, 2023)
- The American Journal of Sports Medicine published a primer for orthopaedic physicians in 2026 noting that despite increasing patient demand, limited expertise exists within sports medicine regarding injectable peptide therapies (Mayfield et al., AJSM, 2026)
- WADA prohibits all growth hormone secretagogues (ipamorelin, MK-677, GHRP-2, GHRP-6, hexarelin) and growth hormone-releasing hormone analogs (CJC-1295, sermorelin, tesamorelin) at all times in competitive sport
- BPC-157 is increasingly used by athletes and clinicians despite no FDA approval, with WADA monitoring the compound but not yet formally listing it as prohibited
The Evidence Landscape: Three Tiers
The peptides used in sports medicine contexts fall into three distinct evidence categories, and conflating them is the source of most confusion in this space.
Tier 1: Human RCT data exists. Collagen peptides (specific bioactive collagen peptides, gelatin hydrolysates) have multiple randomized, double-blind, placebo-controlled trials in human athletes and active populations demonstrating effects on tendon remodeling, joint pain, and musculotendinous stiffness.
Tier 2: Preclinical data only. BPC-157 and TB-500 (thymosin beta-4) have extensive animal model data showing effects on tendon, ligament, muscle, and bone healing. Neither has completed a randomized controlled trial for musculoskeletal indications in humans. The three published human BPC-157 studies are all small pilot studies from a single research group, without placebo controls.
Tier 3: Banned in sport. Growth hormone secretagogues (ipamorelin, MK-677, GHRP-2, GHRP-6, hexarelin), growth hormone-releasing hormone analogs (CJC-1295, sermorelin, tesamorelin), and IGF-1 are prohibited under WADA category S2 at all times. Their use constitutes a doping violation regardless of therapeutic intent. Evidence for performance-enhancing effects is mixed; evidence for detection is improving.
Collagen Peptides: The Strongest Human Evidence
Collagen peptides are the only peptide class in sports medicine with a substantial body of human RCT data. These are orally consumed hydrolyzed collagen fragments (typically 2-10 kDa) that are absorbed from the gut and appear in blood as dipeptides and tripeptides, particularly hydroxyproline-containing peptides that accumulate in connective tissues.
Tendon Remodeling
Balshaw and colleagues conducted a double-blind placebo-controlled study of specific bioactive collagen peptides during 15 weeks of lower body resistance training. The collagen peptide group showed a significantly greater increase in patellar tendon cross-sectional area (11.0%) compared with placebo (4.7%). This is direct evidence that oral collagen peptide supplementation enhances the structural adaptation of tendons to mechanical loading in humans.[1]
Miyamoto and colleagues published a 16-week double-blind RCT in 2025 with 50 healthy young males (25 collagen peptide, 25 placebo). Daily consumption of 10g collagen peptides significantly increased both muscle stiffness and Achilles tendon stiffness, measured by ultrasound shear wave elastography, and improved rate of torque development (explosive strength) for ankle plantar flexion. The muscle cross-sectional area also increased in the collagen group.[2]
Joint Pain Reduction
Schulze and colleagues demonstrated in a 2024 trial that 12 weeks of specific collagen peptide supplementation decreased activity-related joint discomfort in the lower extremity during daily activities in healthy adults across a wide age range. Participants with higher baseline joint discomfort showed the greatest improvements.[3]
Limitations of Collagen Peptide Evidence
The collagen peptide literature, while the strongest in this space, has gaps. Most trials are industry-funded (collagen supplement manufacturers). Sample sizes are small (typically 25-75 per group). Follow-up periods rarely exceed 16 weeks. The mechanism by which ingested collagen peptide fragments stimulate tendon and connective tissue synthesis is still debated, with proposed pathways including direct incorporation into collagen fibrils, stimulation of fibroblast proliferation, and upregulation of collagen gene expression. The current consensus on dosing (15g daily for at least 8 weeks) is based on a relatively thin evidence base. For the full review, see collagen peptides for athletes.
BPC-157: Extensive Preclinical Data, Minimal Human Evidence
Body Protection Compound-157 (BPC-157) is a 15-amino-acid fragment derived from a protein found in human gastric juice. It has become the most discussed peptide in sports medicine, driven by social media coverage and growing clinical use despite a near-total absence of controlled human data.
The Preclinical Evidence
Vasireddi and colleagues published a systematic review in HSS Journal in 2025, screening 544 BPC-157 articles for orthopaedic sports medicine applications. Of the 43 studies meeting inclusion criteria, 42 were animal studies and only 1 was a clinical study. The animal data consistently show accelerated healing of tendons, ligaments, muscles, and bones across multiple injury models and multiple species (rats, rabbits). BPC-157 appears to act through the NO system, upregulation of growth factors (EGF, VEGF), and modulation of inflammation.[4]
McGuire and colleagues conducted a narrative review in 2025 titled "Regeneration or Risk?" evaluating BPC-157's molecular mechanisms, therapeutic potential, and safety concerns. They noted that the compound's angiogenic properties (promoting new blood vessel formation) are beneficial for healing but raise theoretical concerns for patients with cancer or cardiovascular conditions. The review emphasized that the lack of controlled human trials makes it impossible to establish dosing, safety profiles, or efficacy for any musculoskeletal indication.[5]
Matek and colleagues demonstrated in 2025 that oral BPC-157 therapy promoted healing after surgical detachment of the quadriceps muscle from bone in rats, with restored muscle function and tissue architecture. In 2026, the same group published a systematic review comparing BPC-157 with PRP and growth factors for complex musculoskeletal and junctional injuries, concluding that BPC-157 demonstrated consistent efficacy across preclinical models.[6][7]
The Human Evidence Gap
As of early 2026, the only published human BPC-157 data for musculoskeletal applications come from small, open-label pilot studies by a single research group (Dr. Edwin Lee and colleagues in Florida). The interstitial cystitis pilot study in 2024 showed symptomatic improvement in 6 patients but lacked a placebo control.[8] No randomized, placebo-controlled trial of BPC-157 for any orthopaedic or sports medicine indication has been completed and published.
This evidence gap is critical because animal models of tendon and muscle healing do not reliably predict human outcomes. Injury models in rats involve surgically created, standardized lesions that differ fundamentally from the complex, chronic, and mechanically loaded injuries seen in human athletes. Rat tendons heal faster than human tendons, have different mechanical properties, and are not subjected to the repetitive loading patterns that characterize athletic injuries. The history of regenerative medicine is filled with compounds that showed dramatic healing in rodents but produced modest or no benefit in human trials.
The regulatory picture adds another layer of complexity. The FDA classified BPC-157 as a Category 2 compound in 2024, preventing compounding pharmacies from producing it. This classification does not mean the compound is dangerous; it means the FDA determined insufficient evidence exists to support its safety and efficacy for human therapeutic use through the compounding pathway. WADA monitors BPC-157 but has not added it to the prohibited list as of 2026, creating a gray zone where the compound is technically permitted in competition but unavailable through regulated pharmacy channels in the United States.
For the full BPC-157 evidence analysis, see BPC-157 for sports injuries, BPC-157 and athletes: from Joe Rogan to a 12-year-old's parents, and BPC-157 and the FDA.
TB-500 (Thymosin Beta-4): Similar Profile, Different Biology
Thymosin beta-4 (TB-500 is the synthetic version) is a 43-amino-acid peptide involved in cell migration, proliferation, and differentiation. It has established roles in wound healing and tissue repair, with the strongest published data coming from cardiac applications rather than sports medicine.
Zhang and colleagues published in Cardiovascular Research in 2025 a study demonstrating that recombinant human thymosin beta-4 improved ischemic cardiac dysfunction in both mice and patients with acute myocardial infarction, representing one of the few controlled human datasets for this peptide.[9]
For sports medicine applications (tendon healing, muscle repair), thymosin beta-4 data remain preclinical. Animal studies show accelerated corneal wound healing, reduced cardiac fibrosis, and enhanced tendon repair, but no controlled human trial has evaluated TB-500 for any orthopaedic indication. The compound's mechanism (sequestering G-actin to promote cell migration) is well-characterized, but translating this to accelerated human tendon or muscle repair remains unproven. For the full analysis, see TB-500 and athletic recovery.
Growth Hormone Secretagogues: Banned and Detectable
Growth hormone secretagogues (GHS) include ipamorelin, MK-677 (ibutamoren), GHRP-2, GHRP-6, and hexarelin. These peptides stimulate growth hormone release from the pituitary gland by mimicking ghrelin or activating the GHRH receptor. They are prohibited under WADA category S2 ("Peptide Hormones, Growth Factors, Related Substances and Mimetics") at all times, both in and out of competition. GHRH analogs (CJC-1293, CJC-1295, sermorelin, tesamorelin) fall under the same prohibition.
The rationale for their use in athletic contexts centers on growth hormone's anabolic effects: increased lean mass, enhanced recovery, improved sleep quality, and potential connective tissue benefits. The evidence for actual performance enhancement from GH secretagogues, as opposed to supraphysiological GH administration, is weaker than commonly assumed. GH secretagogues elevate endogenous GH secretion within the physiological range for most users, and the performance effects of physiological-range GH fluctuations are debatable. Unlike exogenous GH injection, which produces supraphysiological IGF-1 levels and has demonstrable effects on lean mass, GH secretagogues produce pulsatile GH release that mimics normal physiology, making performance benefits harder to distinguish from placebo effects.
The distinction between GH secretagogues and direct GH administration matters for both athletes and clinicians. MK-677 is orally bioavailable (a rare feature for peptides), making it particularly accessible, but also making its detection straightforward through standard urine testing. Injectable GHRPs and GHRH analogs require subcutaneous administration and have shorter detection windows, but anti-doping laboratories can now detect their metabolites for days to weeks after administration.
Athletes subject to drug testing who use any GH secretagogue risk a doping violation, regardless of whether they obtained the compound through a clinic with a prescription. Therapeutic Use Exemptions (TUEs) for GH secretagogues are exceptionally rare and typically require documented GH deficiency that cannot be treated with approved therapies. For related coverage, see MK-677: the oral growth hormone secretagogue and hexarelin: the most potent GHRP.
What Orthopaedic Physicians Are Being Told
Mayfield and colleagues published a primer in The American Journal of Sports Medicine in 2026 specifically for orthopaedic and sports medicine physicians, acknowledging that patient demand for injectable peptide therapies is outpacing physician knowledge. The primer noted that there is limited expertise within the sports medicine community regarding peptides such as BPC-157, with uncertainty surrounding their clinical application remaining widespread. The authors emphasized the need for physicians to understand both the preclinical evidence landscape and the regulatory status of these compounds before responding to patient requests.[10]
Jozwiak and colleagues reviewed BPC-157's multifunctionality and possible medical applications in 2025, examining both the published literature and patent filings. They noted extensive patent activity around BPC-157 formulations for oral, injectable, and topical delivery, reflecting commercial interest that far outpaces the clinical evidence base.[11]
The Evidence Compared
| Peptide Class | Human RCT Data | Preclinical Data | WADA Status | Strongest Evidence |
|---|---|---|---|---|
| Collagen peptides (oral) | Multiple RCTs | Extensive | Not prohibited | 11% tendon CSA increase vs 4.7% placebo (Balshaw 2023) |
| BPC-157 (injectable) | 0 RCTs (3 pilot studies) | 42+ animal studies | Monitored, not formally prohibited | Consistent preclinical healing across models |
| TB-500 / Thymosin beta-4 | 1 cardiac RCT | Extensive | Prohibited (WADA S2) | Cardiac function improvement in MI patients (Zhang 2025) |
| GH secretagogues (ipamorelin, MK-677, GHRP-2/6) | Limited | Moderate | Prohibited (WADA S2) | GH elevation within physiological range |
| CJC-1295 / Sermorelin | Limited | Moderate | Prohibited (WADA S2) | GH axis stimulation |
Limitations and Open Questions
Collagen peptides work but we do not fully understand why. The mechanism by which ingested collagen peptide fragments (dipeptides and tripeptides absorbed from the gut) stimulate tendon, ligament, and muscle collagen synthesis in specific tissues is not fully characterized. The proposed pathways are plausible but not definitively established.
BPC-157 may work in humans but we do not know. Extrapolating from rat tendon models to human athletic injuries is unreliable. Rats heal differently, load tissues differently, and have different inflammatory responses. The consistent animal results are promising but do not constitute evidence of human efficacy.
The regulatory landscape is unstable. BPC-157 was classified as a Category 2 compound by the FDA in 2024, restricting compounding pharmacies from producing it. WADA monitors BPC-157 but has not formally added it to the prohibited list. These regulatory positions may change, affecting availability and legality for athletes.
Industry funding dominates collagen peptide research. Most collagen peptide RCTs are funded by supplement manufacturers (Gelita, Nitta Gelatin), creating potential conflicts of interest. Independent replication by non-industry researchers would strengthen the evidence base.
Dose-response data are thin. For collagen peptides, the commonly cited 15g daily dose is based on a small number of studies. For BPC-157, no human dosing data exist from controlled trials; all dosing protocols used by clinics are extrapolated from animal studies using allometric scaling formulas that carry substantial uncertainty when translating between species. For GH secretagogues, dose-response relationships for performance outcomes (as opposed to GH elevation) are poorly characterized.
Long-term safety is unknown for most compounds. Collagen peptides have the longest safety record due to widespread commercial use, but even here long-term studies beyond 6 months are sparse. BPC-157's angiogenic properties raise theoretical concerns about tumor vascularization with chronic use, though no human data exist to evaluate this risk. GH secretagogues used chronically could alter pituitary GH feedback loops, and the metabolic consequences of sustained GH axis stimulation beyond the normal physiological range are not fully characterized.
The Source Quality Problem
Beyond the evidence tiers, the quality of information athletes encounter about peptides is itself a significant problem. Most peptide education in the sports medicine space comes from supplement companies, peptide clinics, and social media influencers rather than peer-reviewed research or medical societies. This creates a distorted evidence landscape where BPC-157 anecdotes from podcast guests receive more attention than collagen peptide RCTs published in Medicine and Science in Sports and Exercise.
The AJSM primer by Mayfield and colleagues acknowledged this directly: physicians are being asked about peptides by patients who have already decided to use them, often based on information from non-medical sources. The physician's role becomes one of harm reduction and evidence translation rather than initial recommendation. This dynamic is unusual in sports medicine, where clinicians typically introduce therapeutic options rather than responding to patient-initiated demand for unapproved compounds.
The financial incentives compound the problem. Peptide clinics charge $200-800 per month for injectable BPC-157 and TB-500 protocols, creating a revenue stream that depends on continued demand for compounds without established efficacy. Collagen peptide supplements cost $30-60 per month and have stronger evidence, but generate less clinic revenue because they do not require medical supervision or injection services.
For athletes navigating this landscape, the evidence hierarchy is straightforward even if the marketing is not: collagen peptides have human trial data supporting specific claims about tendon remodeling and joint health; BPC-157 and TB-500 have animal data that is promising but unvalidated in humans; and GH secretagogues are prohibited in competitive sport regardless of their evidence profile. Making decisions based on the evidence tier rather than the marketing volume protects both health and competitive eligibility.
The Bottom Line
The legitimate research in peptides for sports medicine is strongest where the marketing is quietest (collagen peptides with RCT data) and weakest where the hype is loudest (BPC-157 and TB-500 with no controlled human trials). Growth hormone secretagogues occupy a third category: detectable, prohibited, and of uncertain performance benefit.
For related content, see peptide research in sports injury rehabilitation, BPC-157: the body protection compound, how peptide doping is detected, and how growth hormone peptides affect sleep quality.
The Bottom Line
Peptides in sports medicine split into three evidence tiers. Collagen peptides have multiple double-blind RCTs showing tendon remodeling (11% cross-sectional area increase), increased muscle-tendon stiffness, and reduced joint pain. BPC-157 has 42+ animal studies showing musculoskeletal healing but zero randomized controlled trials in humans for any orthopaedic indication. Growth hormone secretagogues are prohibited by WADA under category S2 at all times. The evidence gap between marketing claims and published research remains the defining feature of the peptide sports medicine landscape.